Investigating dapagliflozin's effects on heart function in chronic kidney disease patients

A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease

This study is testing if the medication dapagliflozin can improve heart function in adults with chronic kidney disease who are already taking certain heart medications.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 222 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Herlev and Gentofte Hospital (other)
• Locations: 1 site (Copenhagen)
• Trial ID: NCT05359263 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the impact of dapagliflozin on echocardiographic measures of cardiac structure and function in adults with chronic kidney disease (CKD). It is a 6-month, randomized, double-blind, placebo-controlled study involving approximately 222 participants who will receive either 10 mg of dapagliflozin or a placebo. Participants will undergo various assessments, including echocardiography, pulse wave velocity, and quality of life evaluations, at baseline and after 6 months of treatment. The study focuses on patients with CKD who are already on stable doses of ACE inhibitors or ARBs.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with chronic kidney disease and stable treatment with ACE inhibitors or ARBs.

Not a fit: Patients with severe kidney impairment or those not on stable ACEi/ARB treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve heart health outcomes for patients with chronic kidney disease.

How similar studies have performed: Other studies have shown promising results with dapagliflozin in similar patient populations, indicating potential for success.

Eligibility criteria

Inclusion Criteria:

* Signed informed consent
* ≥ 18 years of age
* Chronic kidney disease (CKD), defined as evidence of decreased eGFR (eGFR ≥20 and \<60 mL/minute per 1.73 m2) or between eGFR ≥60 and \<90 mL/minute per 1.73 m2 with urinary albumin:creatinine ratio ≥200 mg/g or protein:creatinine ratio ≥300 mg/g
* Stable treatment with clinically appropriate doses of ACEi/ARB among CKD patients with proteinuria and uptitrated to maximal recommended or tolerated dose for at least 4 weeks before randomization, if not medically contraindicated
* For patients with type 2 diabetes:

Stable antihyperglycemic treatment \> 30 days before screening

* Female patients should either not be of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing one of the following methods of contraception throughout the study and for 30 days after study completion: Hormonal contraception (oral contraceptives, contraceptive implant, injectable birth control, contraceptive patch, or vaginal ring) or intrauterine device
* Ability to understand and read Danish

Exclusion Criteria:

* Type 1 diabetes
* For patients with type 2 diabetes:

History of diabetic ketoacidosis

* Patients undergoing dialysis
* History of organ transplant
* Treatment with SGLT2 inhibitor within 8 weeks prior to enrolment
* Known allergy or hypersensitivity to SGLT2 inhibitors or Placebo ingredients
* Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks of enrolment
* Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment
* Any condition outside the renal and cardiovascular study area with a life expectancy of \<2 years based on investigator's clinical judgement
* Hepatic impairment (aspartate transaminase or alanine transaminase \>3 times the upper limit of normal \[ULN\] or total bilirubin \>2 times the ULN at the time of enrolment)
* Known blood-borne diseases, such as Hepatitis A, B, C, D, and E, and Human immunodeficiency virus (HIV) types 1 and 2, Ebola, Lassa fever virus.
* Female patients who are pregnant, lactating, or are considering becoming pregnant during the study or for 6 months after study completion
* Participation in another clinical study with an investigational product within the last month prior to enrolment
* Inability to understand or comply with the investigational product, procedures, and/or follow-up or any conditions that may prevent the participant to complete the study

Where this trial is running

Copenhagen

• Gentofte Hospital — Copenhagen, Denmark (RECRUITING)

Study contacts

• Study coordinator: Katja Vu Bartholdy, MD

Conditions: Chronic Kidney Diseases